Update on the safety of testosterone therapy in cardiac disease

Bibliography

• Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5(12):673-81
   PubMed Web of Science ®Google Scholar
• Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010;21(8):496-503
   PubMed Web of Science ®Google Scholar
• Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008;28(12):1511-22
   PubMed Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 2009;210(1):232-6
   PubMed Web of Science ®Google Scholar
• Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009;51(5-6):303-13
   PubMed Web of Science ®Google Scholar
• English KM, Mandour O, Steeds RP, Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21(11):890-4
   PubMed Web of Science ®Google Scholar
• Sieminska L, Wojciechowska C, Swietochowska E, Serum free testosterone in men with coronary artery atherosclerosis. Med Sci Monit 2003;9(5):CR162-6
   Google Scholar
• Rosano GM, Sheiban I, Massaro R, Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007;19(2):176-82
   PubMed Web of Science ®Google Scholar
• Haring R, Volzke H, Steveling A, Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31(12):1494-501
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96(22):1821-5
   PubMed Web of Science ®Google Scholar
• Tsai HK, D'Amico AV, Sadetsky N, Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99(20):1516-24
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Fokerd E, Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective population study. Circulation 2007;116(23):2694-701
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78(3):539-45
   PubMed Web of Science ®Google Scholar
• Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 1993;13(4):517-20
   PubMedGoogle Scholar
• Isidori AM, Giannetta E, Greco EA, Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63(3):280-93
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7(10):3495-503
   PubMed Web of Science ®Google Scholar
• Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007;116(21):2427-34
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005;96(12B):67M-72M
   Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73(5):602-12
   PubMed Web of Science ®Google Scholar
• Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003;51(1):101-15, discussion 15
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000;102(16):1906-11
   PubMed Web of Science ®Google Scholar
• Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977;39(11):1217-22
   PubMedGoogle Scholar
• Anker SD, Chua TP, Ponikowski P, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96(2):526-34
   PubMed Web of Science ®Google Scholar
• Caminiti G, Volterrani M, Iellamo F, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54(10):919-27
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, West JN, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006;27(1):57-64
   PubMed Web of Science ®Google Scholar
• Iellamo F, Volterrani M, Caminiti G, Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56(16):1310-16
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Ma J, Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88(16):1118-26
   PubMed Web of Science ®Google Scholar
• Ling S, Dai A, Williams MR, Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology 2002;143(3):1119-25
   PubMed Web of Science ®Google Scholar
• Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol 2004;6(Suppl 6):S22-9
   Google Scholar
• Wang C, Cunningham G, Dobs A, Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89(5):2085-98
   PubMed Web of Science ®Google Scholar
• Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006;102(1-5):261-6
   PubMed Web of Science ®Google Scholar
• Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9(1):14-18
   PubMed Web of Science ®Google Scholar
• Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998;41(1):1-15
   PubMed Web of Science ®Google Scholar
• Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 2010;106(6):893-901
   PubMed Web of Science ®Google Scholar
• Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24(10):909-15
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109-22
   PubMed Web of Science ®Google Scholar
• O'Connell MD, Roberts SA, Srinivas-Shankar U, Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 2010. [Epub ahead of print]
   Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(6):2560-75
   PubMed Web of Science ®Google Scholar
• Haddad RM, Kennedy CC, Caples SM, Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82(1):29-39
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359(19):2005-17
   PubMed Web of Science ®Google Scholar
• Basaria S, Dobs AS. Safety and adverse effects of androgens: how to counsel patients. Mayo Clin Proc 2004;79(Suppl 4):S25-32
   Google Scholar
• Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63(1):63-6
   PubMed Web of Science ®Google Scholar
• Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2010;12(6):R98
   Google Scholar
• Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7(11):3758-64
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95(6):2536-59
   PubMed Web of Science ®Google Scholar